Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Treasury Shares (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Treasury Shares for 14 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 55.59% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, up 55.59%, and an annual FY2025 reading of $1.3 million, up 55.59% over the prior year.
  • Treasury Shares was $1.3 million for Q4 2025 at Karyopharm Therapeutics, up from $850738.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $7.7 million in Q4 2023 and bottomed at $850738.0 in Q4 2024.
  • Average Treasury Shares over 5 years is $3.1 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Treasury Shares soared 125.3% in 2023, then plummeted 88.9% in 2024.
  • Year by year, Treasury Shares stood at $2.3 million in 2021, then skyrocketed by 47.91% to $3.4 million in 2022, then surged by 125.3% to $7.7 million in 2023, then tumbled by 88.9% to $850738.0 in 2024, then surged by 55.59% to $1.3 million in 2025.
  • Business Quant data shows Treasury Shares for KPTI at $1.3 million in Q4 2025, $850738.0 in Q4 2024, and $7.7 million in Q4 2023.